Malignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors
The Spanish Post‐Heart‐Transplant Tumour Registry comprises data on neoplasia following heart transplantation (HT) for all Spanish HT patients (1984–2003). This retrospective analysis of 3393 patients investigated the incidence and prognosis of neoplasia, and the influence of antiviral prophylaxis....
Gespeichert in:
| Veröffentlicht in: | American journal of transplantation 2008-05, Vol.8 (5), p.1031-1039 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1039 |
|---|---|
| container_issue | 5 |
| container_start_page | 1031 |
| container_title | American journal of transplantation |
| container_volume | 8 |
| creator | Crespo‐Leiro, M. G. Alonso‐Pulpón, L. Vázquez de Prada, J. A. Almenar, L. Arizón, J. M. Brossa, V. Delgado, J. F. Fernandez‐Yañez, J. Manito, N. Rábago, G. Lage, E. Roig, E. Diaz‐Molina, B. Pascual, D. Muñiz, J. |
| description | The Spanish Post‐Heart‐Transplant Tumour Registry comprises data on neoplasia following heart transplantation (HT) for all Spanish HT patients (1984–2003). This retrospective analysis of 3393 patients investigated the incidence and prognosis of neoplasia, and the influence of antiviral prophylaxis. About 50% of post‐HT neoplasias were cutaneous, and 10% lymphomas. The cumulative incidence of skin cancers and other nonlymphoma cancers increased with age at HT and with time post‐HT (from respectively 5.2 and 8.9 per 1000 person‐years in the first year to 14.8 and 12.6 after 10 years), and was greater among men than women. None of these trends held for lymphomas. Induction therapy other than with IL2R‐blockers generally increased the risk of neoplasia except when acyclovir was administered prophylactically during the first 3 months post‐HT; prophylactic acyclovir halved the risk of lymphoma, regardless of other therapies. Institution of MMF during the first 3 months post‐HT reduced the incidence of skin cancer independently of the effects of sex, age group, pre‐HT smoking, use of tacrolimus in the first 3 months, induction treatment and antiviral treatment. Five‐year survival rates after first tumor diagnosis were 74% for skin cancer, 20% for lymphoma and 32% for other tumors.
Analysis of follow‐up data for 3393 Spanish heart transplant patients shows skin cancer to have a more favorable prognosis than other tumors, and suggests that prophylactic acyclovir counteracts the risk of neoplasia associated with certain induction treatments. |
| doi_str_mv | 10.1111/j.1600-6143.2008.02196.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69110714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69110714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5446-5b8df93454657f34460be61bcdca5e505855bafd0505645afb388455094eb24f3</originalsourceid><addsrcrecordid>eNqNkMtOAyEUhonReH8Fw0ZXduRexsRFY7xGozF1TRgGDHXKVJhG-_YytqlLZcOfc74DJx8AEKMC53M2KbBAaCAwowVBSBaI4FIUXxtgd93YXGfKd8BeShOE8JBIsg12sGRYDGm5Cx4fdePfgg5mAUeusxHeWh07OI46pFmjQ6c734ZzeBeMr20w9hQ-x_YttMknqEMNX3x6h9fadG1MB2DL6SbZw9W9D16vr8aXt4OHp5u7y9HDwHDGxIBXsnYlZZwJPnQ0l1BlBa5MbTS3HHHJeaVdjXIUjGtXUSkZ56hktiLM0X1wsnx3FtuPuU2dmvpkbJP3te08KVFijIZZwl8gQdmI5D0ol6CJbUrROjWLfqrjQmGkeudqonqdqlereufqx7n6yqNHqz_m1dTWv4MryRk4XgE6Gd24rNb4tOYIooSKkmTuYsl9-sYu_r2AGt2P-0S_Ad7jmzo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20728854</pqid></control><display><type>article</type><title>Malignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Crespo‐Leiro, M. G. ; Alonso‐Pulpón, L. ; Vázquez de Prada, J. A. ; Almenar, L. ; Arizón, J. M. ; Brossa, V. ; Delgado, J. F. ; Fernandez‐Yañez, J. ; Manito, N. ; Rábago, G. ; Lage, E. ; Roig, E. ; Diaz‐Molina, B. ; Pascual, D. ; Muñiz, J.</creator><creatorcontrib>Crespo‐Leiro, M. G. ; Alonso‐Pulpón, L. ; Vázquez de Prada, J. A. ; Almenar, L. ; Arizón, J. M. ; Brossa, V. ; Delgado, J. F. ; Fernandez‐Yañez, J. ; Manito, N. ; Rábago, G. ; Lage, E. ; Roig, E. ; Diaz‐Molina, B. ; Pascual, D. ; Muñiz, J.</creatorcontrib><description>The Spanish Post‐Heart‐Transplant Tumour Registry comprises data on neoplasia following heart transplantation (HT) for all Spanish HT patients (1984–2003). This retrospective analysis of 3393 patients investigated the incidence and prognosis of neoplasia, and the influence of antiviral prophylaxis. About 50% of post‐HT neoplasias were cutaneous, and 10% lymphomas. The cumulative incidence of skin cancers and other nonlymphoma cancers increased with age at HT and with time post‐HT (from respectively 5.2 and 8.9 per 1000 person‐years in the first year to 14.8 and 12.6 after 10 years), and was greater among men than women. None of these trends held for lymphomas. Induction therapy other than with IL2R‐blockers generally increased the risk of neoplasia except when acyclovir was administered prophylactically during the first 3 months post‐HT; prophylactic acyclovir halved the risk of lymphoma, regardless of other therapies. Institution of MMF during the first 3 months post‐HT reduced the incidence of skin cancer independently of the effects of sex, age group, pre‐HT smoking, use of tacrolimus in the first 3 months, induction treatment and antiviral treatment. Five‐year survival rates after first tumor diagnosis were 74% for skin cancer, 20% for lymphoma and 32% for other tumors.
Analysis of follow‐up data for 3393 Spanish heart transplant patients shows skin cancer to have a more favorable prognosis than other tumors, and suggests that prophylactic acyclovir counteracts the risk of neoplasia associated with certain induction treatments.</description><identifier>ISSN: 1600-6135</identifier><identifier>EISSN: 1600-6143</identifier><identifier>DOI: 10.1111/j.1600-6143.2008.02196.x</identifier><identifier>PMID: 18416739</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antibodies ; antilymphocyte antivirals ; Antiviral agents ; Biological and medical sciences ; Epidemiology ; Follow-Up Studies ; General aspects ; heart transplantation ; Heart Transplantation - adverse effects ; Humans ; Incidence ; malignancy ; Medical sciences ; Middle Aged ; Neoplasms - epidemiology ; Pharmacology. Drug treatments ; Postoperative Complications - epidemiology ; prognosis ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Retrospective Studies ; Risk Factors ; Spain ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Time Factors</subject><ispartof>American journal of transplantation, 2008-05, Vol.8 (5), p.1031-1039</ispartof><rights>2008 The Authors Journal compilation © 2008 The American Society of Transplantation and the American Society of Transplant Surgeons</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5446-5b8df93454657f34460be61bcdca5e505855bafd0505645afb388455094eb24f3</citedby><cites>FETCH-LOGICAL-c5446-5b8df93454657f34460be61bcdca5e505855bafd0505645afb388455094eb24f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-6143.2008.02196.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-6143.2008.02196.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20323692$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18416739$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crespo‐Leiro, M. G.</creatorcontrib><creatorcontrib>Alonso‐Pulpón, L.</creatorcontrib><creatorcontrib>Vázquez de Prada, J. A.</creatorcontrib><creatorcontrib>Almenar, L.</creatorcontrib><creatorcontrib>Arizón, J. M.</creatorcontrib><creatorcontrib>Brossa, V.</creatorcontrib><creatorcontrib>Delgado, J. F.</creatorcontrib><creatorcontrib>Fernandez‐Yañez, J.</creatorcontrib><creatorcontrib>Manito, N.</creatorcontrib><creatorcontrib>Rábago, G.</creatorcontrib><creatorcontrib>Lage, E.</creatorcontrib><creatorcontrib>Roig, E.</creatorcontrib><creatorcontrib>Diaz‐Molina, B.</creatorcontrib><creatorcontrib>Pascual, D.</creatorcontrib><creatorcontrib>Muñiz, J.</creatorcontrib><title>Malignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors</title><title>American journal of transplantation</title><addtitle>Am J Transplant</addtitle><description>The Spanish Post‐Heart‐Transplant Tumour Registry comprises data on neoplasia following heart transplantation (HT) for all Spanish HT patients (1984–2003). This retrospective analysis of 3393 patients investigated the incidence and prognosis of neoplasia, and the influence of antiviral prophylaxis. About 50% of post‐HT neoplasias were cutaneous, and 10% lymphomas. The cumulative incidence of skin cancers and other nonlymphoma cancers increased with age at HT and with time post‐HT (from respectively 5.2 and 8.9 per 1000 person‐years in the first year to 14.8 and 12.6 after 10 years), and was greater among men than women. None of these trends held for lymphomas. Induction therapy other than with IL2R‐blockers generally increased the risk of neoplasia except when acyclovir was administered prophylactically during the first 3 months post‐HT; prophylactic acyclovir halved the risk of lymphoma, regardless of other therapies. Institution of MMF during the first 3 months post‐HT reduced the incidence of skin cancer independently of the effects of sex, age group, pre‐HT smoking, use of tacrolimus in the first 3 months, induction treatment and antiviral treatment. Five‐year survival rates after first tumor diagnosis were 74% for skin cancer, 20% for lymphoma and 32% for other tumors.
Analysis of follow‐up data for 3393 Spanish heart transplant patients shows skin cancer to have a more favorable prognosis than other tumors, and suggests that prophylactic acyclovir counteracts the risk of neoplasia associated with certain induction treatments.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antibodies</subject><subject>antilymphocyte antivirals</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Epidemiology</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>heart transplantation</subject><subject>Heart Transplantation - adverse effects</subject><subject>Humans</subject><subject>Incidence</subject><subject>malignancy</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasms - epidemiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Postoperative Complications - epidemiology</subject><subject>prognosis</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Spain</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Time Factors</subject><issn>1600-6135</issn><issn>1600-6143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOAyEUhonReH8Fw0ZXduRexsRFY7xGozF1TRgGDHXKVJhG-_YytqlLZcOfc74DJx8AEKMC53M2KbBAaCAwowVBSBaI4FIUXxtgd93YXGfKd8BeShOE8JBIsg12sGRYDGm5Cx4fdePfgg5mAUeusxHeWh07OI46pFmjQ6c734ZzeBeMr20w9hQ-x_YttMknqEMNX3x6h9fadG1MB2DL6SbZw9W9D16vr8aXt4OHp5u7y9HDwHDGxIBXsnYlZZwJPnQ0l1BlBa5MbTS3HHHJeaVdjXIUjGtXUSkZ56hktiLM0X1wsnx3FtuPuU2dmvpkbJP3te08KVFijIZZwl8gQdmI5D0ol6CJbUrROjWLfqrjQmGkeudqonqdqlereufqx7n6yqNHqz_m1dTWv4MryRk4XgE6Gd24rNb4tOYIooSKkmTuYsl9-sYu_r2AGt2P-0S_Ad7jmzo</recordid><startdate>200805</startdate><enddate>200805</enddate><creator>Crespo‐Leiro, M. G.</creator><creator>Alonso‐Pulpón, L.</creator><creator>Vázquez de Prada, J. A.</creator><creator>Almenar, L.</creator><creator>Arizón, J. M.</creator><creator>Brossa, V.</creator><creator>Delgado, J. F.</creator><creator>Fernandez‐Yañez, J.</creator><creator>Manito, N.</creator><creator>Rábago, G.</creator><creator>Lage, E.</creator><creator>Roig, E.</creator><creator>Diaz‐Molina, B.</creator><creator>Pascual, D.</creator><creator>Muñiz, J.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U1</scope><scope>7U2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200805</creationdate><title>Malignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors</title><author>Crespo‐Leiro, M. G. ; Alonso‐Pulpón, L. ; Vázquez de Prada, J. A. ; Almenar, L. ; Arizón, J. M. ; Brossa, V. ; Delgado, J. F. ; Fernandez‐Yañez, J. ; Manito, N. ; Rábago, G. ; Lage, E. ; Roig, E. ; Diaz‐Molina, B. ; Pascual, D. ; Muñiz, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5446-5b8df93454657f34460be61bcdca5e505855bafd0505645afb388455094eb24f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antibodies</topic><topic>antilymphocyte antivirals</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Epidemiology</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>heart transplantation</topic><topic>Heart Transplantation - adverse effects</topic><topic>Humans</topic><topic>Incidence</topic><topic>malignancy</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasms - epidemiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Postoperative Complications - epidemiology</topic><topic>prognosis</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Spain</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crespo‐Leiro, M. G.</creatorcontrib><creatorcontrib>Alonso‐Pulpón, L.</creatorcontrib><creatorcontrib>Vázquez de Prada, J. A.</creatorcontrib><creatorcontrib>Almenar, L.</creatorcontrib><creatorcontrib>Arizón, J. M.</creatorcontrib><creatorcontrib>Brossa, V.</creatorcontrib><creatorcontrib>Delgado, J. F.</creatorcontrib><creatorcontrib>Fernandez‐Yañez, J.</creatorcontrib><creatorcontrib>Manito, N.</creatorcontrib><creatorcontrib>Rábago, G.</creatorcontrib><creatorcontrib>Lage, E.</creatorcontrib><creatorcontrib>Roig, E.</creatorcontrib><creatorcontrib>Diaz‐Molina, B.</creatorcontrib><creatorcontrib>Pascual, D.</creatorcontrib><creatorcontrib>Muñiz, J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crespo‐Leiro, M. G.</au><au>Alonso‐Pulpón, L.</au><au>Vázquez de Prada, J. A.</au><au>Almenar, L.</au><au>Arizón, J. M.</au><au>Brossa, V.</au><au>Delgado, J. F.</au><au>Fernandez‐Yañez, J.</au><au>Manito, N.</au><au>Rábago, G.</au><au>Lage, E.</au><au>Roig, E.</au><au>Diaz‐Molina, B.</au><au>Pascual, D.</au><au>Muñiz, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Malignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors</atitle><jtitle>American journal of transplantation</jtitle><addtitle>Am J Transplant</addtitle><date>2008-05</date><risdate>2008</risdate><volume>8</volume><issue>5</issue><spage>1031</spage><epage>1039</epage><pages>1031-1039</pages><issn>1600-6135</issn><eissn>1600-6143</eissn><abstract>The Spanish Post‐Heart‐Transplant Tumour Registry comprises data on neoplasia following heart transplantation (HT) for all Spanish HT patients (1984–2003). This retrospective analysis of 3393 patients investigated the incidence and prognosis of neoplasia, and the influence of antiviral prophylaxis. About 50% of post‐HT neoplasias were cutaneous, and 10% lymphomas. The cumulative incidence of skin cancers and other nonlymphoma cancers increased with age at HT and with time post‐HT (from respectively 5.2 and 8.9 per 1000 person‐years in the first year to 14.8 and 12.6 after 10 years), and was greater among men than women. None of these trends held for lymphomas. Induction therapy other than with IL2R‐blockers generally increased the risk of neoplasia except when acyclovir was administered prophylactically during the first 3 months post‐HT; prophylactic acyclovir halved the risk of lymphoma, regardless of other therapies. Institution of MMF during the first 3 months post‐HT reduced the incidence of skin cancer independently of the effects of sex, age group, pre‐HT smoking, use of tacrolimus in the first 3 months, induction treatment and antiviral treatment. Five‐year survival rates after first tumor diagnosis were 74% for skin cancer, 20% for lymphoma and 32% for other tumors.
Analysis of follow‐up data for 3393 Spanish heart transplant patients shows skin cancer to have a more favorable prognosis than other tumors, and suggests that prophylactic acyclovir counteracts the risk of neoplasia associated with certain induction treatments.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18416739</pmid><doi>10.1111/j.1600-6143.2008.02196.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1600-6135 |
| ispartof | American journal of transplantation, 2008-05, Vol.8 (5), p.1031-1039 |
| issn | 1600-6135 1600-6143 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69110714 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antibodies antilymphocyte antivirals Antiviral agents Biological and medical sciences Epidemiology Follow-Up Studies General aspects heart transplantation Heart Transplantation - adverse effects Humans Incidence malignancy Medical sciences Middle Aged Neoplasms - epidemiology Pharmacology. Drug treatments Postoperative Complications - epidemiology prognosis Public health. Hygiene Public health. Hygiene-occupational medicine Retrospective Studies Risk Factors Spain Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Time Factors |
| title | Malignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A45%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Malignancy%20After%20Heart%20Transplantation:%20Incidence,%20Prognosis%20and%20Risk%20Factors&rft.jtitle=American%20journal%20of%20transplantation&rft.au=Crespo%E2%80%90Leiro,%20M.%20G.&rft.date=2008-05&rft.volume=8&rft.issue=5&rft.spage=1031&rft.epage=1039&rft.pages=1031-1039&rft.issn=1600-6135&rft.eissn=1600-6143&rft_id=info:doi/10.1111/j.1600-6143.2008.02196.x&rft_dat=%3Cproquest_cross%3E69110714%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20728854&rft_id=info:pmid/18416739&rfr_iscdi=true |